T. Rowe Price Associates’s Allogene Therapeutics ALLO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$4.56M Sell
4,030,872
-175,132
-4% -$198K ﹤0.01% 1299
2025
Q1
$6.14M Sell
4,206,004
-279,568
-6% -$408K ﹤0.01% 1213
2024
Q4
$9.56M Sell
4,485,572
-353,171
-7% -$752K ﹤0.01% 1160
2024
Q3
$13.6M Sell
4,838,743
-951,799
-16% -$2.67M ﹤0.01% 1081
2024
Q2
$13.5M Buy
5,790,542
+1,612,923
+39% +$3.76M ﹤0.01% 1052
2024
Q1
$18.7M Buy
4,177,619
+1,806,147
+76% +$8.07M ﹤0.01% 988
2023
Q4
$7.61M Sell
2,371,472
-35,875
-1% -$115K ﹤0.01% 1143
2023
Q3
$7.63M Sell
2,407,347
-2,924,053
-55% -$9.27M ﹤0.01% 1107
2023
Q2
$26.5M Sell
5,331,400
-998,904
-16% -$4.96M ﹤0.01% 857
2023
Q1
$31.3M Buy
6,330,304
+388,507
+7% +$1.92M ﹤0.01% 810
2022
Q4
$37.4M Buy
5,941,797
+34,481
+0.6% +$217K 0.01% 740
2022
Q3
$63.8M Buy
5,907,316
+348,140
+6% +$3.76M 0.01% 585
2022
Q2
$63.4M Buy
5,559,176
+1,292,441
+30% +$14.7M 0.01% 804
2022
Q1
$38.9M Buy
4,266,735
+1,015,207
+31% +$9.25M ﹤0.01% 1055
2021
Q4
$48.5M Sell
3,251,528
-1,087,463
-25% -$16.2M ﹤0.01% 1017
2021
Q3
$112M Buy
4,338,991
+803,807
+23% +$20.7M 0.01% 731
2021
Q2
$92.2M Buy
3,535,184
+78,431
+2% +$2.05M 0.01% 808
2021
Q1
$122M Sell
3,456,753
-103,040
-3% -$3.64M 0.01% 709
2020
Q4
$89.8M Sell
3,559,793
-17,891
-0.5% -$452K 0.01% 754
2020
Q3
$135M Sell
3,577,684
-213,102
-6% -$8.04M 0.02% 582
2020
Q2
$162M Buy
3,790,786
+1,586,252
+72% +$67.9M 0.02% 515
2020
Q1
$42.9M Sell
2,204,534
-265,976
-11% -$5.17M 0.01% 831
2019
Q4
$64.2M Sell
2,470,510
-48,162
-2% -$1.25M 0.01% 817
2019
Q3
$68.6M Sell
2,518,672
-4,234
-0.2% -$115K 0.01% 745
2019
Q2
$67.7M Buy
2,522,906
+3,398
+0.1% +$91.2K 0.01% 768
2019
Q1
$70.9M Buy
2,519,508
+7,510
+0.3% +$211K 0.01% 737
2018
Q4
$65.9M Buy
+2,511,998
New +$65.9M 0.01% 722